Contineum Therapeutics (NASDAQ:CTNM) Now Covered by Analysts at William Blair

William Blair assumed coverage on shares of Contineum Therapeutics (NASDAQ:CTNM) in a research note issued to investors on Friday, Marketbeat.com reports. The firm issued an outperform rating on the stock.

A number of other brokerages have also issued reports on CTNM. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $31.00 price target on shares of Contineum Therapeutics in a research note on Thursday, May 15th. Jones Trading began coverage on Contineum Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $23.00 price target for the company. Robert W. Baird decreased their price target on Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, March 7th. Finally, Morgan Stanley decreased their price target on Contineum Therapeutics from $25.00 to $20.00 and set an “overweight” rating for the company in a research note on Monday, May 19th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Contineum Therapeutics currently has an average rating of “Buy” and a consensus price target of $22.50.

Contineum Therapeutics Price Performance

CTNM opened at $4.76 on Friday. The stock’s 50 day moving average price is $4.16 and its 200 day moving average price is $7.79. The stock has a market cap of $123.14 million, a P/E ratio of -2.42 and a beta of 0.52. Contineum Therapeutics has a 12 month low of $3.35 and a 12 month high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Equities analysts anticipate that Contineum Therapeutics will post -2.01 EPS for the current year.

Institutional Investors Weigh In On Contineum Therapeutics

Several large investors have recently modified their holdings of CTNM. Strs Ohio bought a new stake in shares of Contineum Therapeutics during the 1st quarter worth $27,000. Legal & General Group Plc boosted its stake in shares of Contineum Therapeutics by 74.0% during the 4th quarter. Legal & General Group Plc now owns 3,631 shares of the company’s stock worth $53,000 after acquiring an additional 1,544 shares in the last quarter. Corebridge Financial Inc. boosted its stake in shares of Contineum Therapeutics by 73.1% during the 4th quarter. Corebridge Financial Inc. now owns 5,215 shares of the company’s stock worth $76,000 after acquiring an additional 2,202 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Contineum Therapeutics by 90.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,860 shares of the company’s stock worth $86,000 after acquiring an additional 2,783 shares in the last quarter. Finally, Nuveen LLC bought a new stake in shares of Contineum Therapeutics during the 1st quarter worth $93,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).